Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ambulatory blood pressure monitoring study of TLANDO

Trial Profile

An ambulatory blood pressure monitoring study of TLANDO

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Nov 2018 New trial record
    • 07 Nov 2018 According to the Lipocine media release, results from the trial are expected in the first quarter of 2019. This study is being conducted to address the blood pressure related concern cited in the FDA's Complete Response Letter issued May 2018, in response to Testosterone-undecanoate NDA.
    • 01 Nov 2018 Status changed from recruiting to active, no longer recruiting, as reported in the Lipocine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top